151 related articles for article (PubMed ID: 35202740)
1. Dosimetric parameters related to occurrence of distant metastases and regional nodal relapse after SBRT for early-stage non-small cell lung cancer.
Lalonde R; Abdelhakiem M; Keller A; Huq MS
Radiother Oncol; 2022 Apr; 169():90-95. PubMed ID: 35202740
[TBL] [Abstract][Full Text] [Related]
2. Can dose outside the PTV influence the risk of distant metastases in stage I lung cancer patients treated with stereotactic body radiotherapy (SBRT)?
Diamant A; Chatterjee A; Faria S; Naqa IE; Bahig H; Filion E; Robinson C; Al-Halabi H; Seuntjens J
Radiother Oncol; 2018 Sep; 128(3):513-519. PubMed ID: 29801721
[TBL] [Abstract][Full Text] [Related]
3. Assessment of Monte Carlo algorithm for compliance with RTOG 0915 dosimetric criteria in peripheral lung cancer patients treated with stereotactic body radiotherapy.
Pokhrel D; Sood S; Badkul R; Jiang H; McClinton C; Lominska C; Kumar P; Wang F
J Appl Clin Med Phys; 2016 May; 17(3):277-293. PubMed ID: 27167284
[TBL] [Abstract][Full Text] [Related]
4. Predictors of Nodal and Metastatic Failure in Early Stage Non-small-cell Lung Cancer After Stereotactic Body Radiation Therapy.
Cerra-Franco A; Liu S; Azar M; Shiue K; Freije S; Hinton J; Deig CR; Edwards D; Estabrook NC; Ellsworth SG; Huang K; Diab K; Langer MP; Zellars R; Kong FM; Wan J; Lautenschlaeger T
Clin Lung Cancer; 2019 May; 20(3):186-193.e3. PubMed ID: 30711394
[TBL] [Abstract][Full Text] [Related]
5. Comparing local control and distant metastasis in NSCLC patients between CyberKnife and conventional SBRT.
Diamant A; Heng VJ; Chatterjee A; Faria S; Bahig H; Filion E; Doucet R; Khosrow-Khavar F; Naqa IE; Seuntjens J
Radiother Oncol; 2020 Mar; 144():201-208. PubMed ID: 32044418
[TBL] [Abstract][Full Text] [Related]
6. Predictive factors for local control in primary and metastatic lung tumours after four to five fraction stereotactic ablative body radiotherapy: a single institution's comprehensive experience.
Thibault I; Poon I; Yeung L; Erler D; Kim A; Keller B; Lochray F; Jain S; Soliman H; Cheung P
Clin Oncol (R Coll Radiol); 2014 Nov; 26(11):713-9. PubMed ID: 25085765
[TBL] [Abstract][Full Text] [Related]
7. Dose-response relationship with clinical outcome for lung stereotactic body radiotherapy (SBRT) delivered via online image guidance.
Kestin L; Grills I; Guckenberger M; Belderbos J; Hope AJ; Werner-Wasik M; Sonke JJ; Bissonnette JP; Xiao Y; Yan D;
Radiother Oncol; 2014 Mar; 110(3):499-504. PubMed ID: 24630539
[TBL] [Abstract][Full Text] [Related]
8. The significance of PTV dose coverage on cancer control outcomes in early stage non-small cell lung cancer patients treated with highly ablative stereotactic body radiation therapy.
Shaverdian N; Tenn S; Veruttipong D; Wang J; Hegde J; Lee C; Cao M; Agazaryan N; Steinberg M; Kupelian P; Lee P
Br J Radiol; 2016; 89(1059):20150963. PubMed ID: 26764282
[TBL] [Abstract][Full Text] [Related]
9. Impact of dose to lung outside the planning target volume on distant metastasis or progression after SBRT for early-stage non-small cell lung cancer.
Hughes RT; Steber CR; Jacobson TJ; Farris MK
Radiother Oncol; 2021 Jun; 159():28-32. PubMed ID: 33711410
[TBL] [Abstract][Full Text] [Related]
10. Factors important for efficacy of stereotactic body radiotherapy of medically inoperable stage I lung cancer. A retrospective analysis of patients treated in the Nordic countries.
Baumann P; Nyman J; Lax I; Friesland S; Hoyer M; Rehn Ericsson S; Johansson KA; Ekberg L; Morhed E; Paludan M; Wittgren L; Blomgren H; Lewensohn R
Acta Oncol; 2006; 45(7):787-95. PubMed ID: 16982541
[TBL] [Abstract][Full Text] [Related]
11. Stereotactic body radiotherapy for centrally located early-stage non-small cell lung cancer or lung metastases from the RSSearch(®) patient registry.
Davis JN; Medbery C; Sharma S; Pablo J; Kimsey F; Perry D; Muacevic A; Mahadevan A
Radiat Oncol; 2015 May; 10():113. PubMed ID: 25975848
[TBL] [Abstract][Full Text] [Related]
12. Local control and toxicity in a large cohort of central lung tumors treated with stereotactic body radiation therapy.
Modh A; Rimner A; Williams E; Foster A; Shah M; Shi W; Zhang Z; Gelblum DY; Rosenzweig KE; Yorke ED; Jackson A; Wu AJ
Int J Radiat Oncol Biol Phys; 2014 Dec; 90(5):1168-76. PubMed ID: 25303891
[TBL] [Abstract][Full Text] [Related]
13. Incidental prophylactic nodal irradiation and patterns of nodal relapse in inoperable early stage NSCLC patients treated with SBRT: a case-matched analysis.
Lao L; Hope AJ; Maganti M; Brade A; Bezjak A; Saibishkumar EP; Giuliani M; Sun A; Cho BC
Int J Radiat Oncol Biol Phys; 2014 Sep; 90(1):209-15. PubMed ID: 24997639
[TBL] [Abstract][Full Text] [Related]
14. Impact of Tumor Size on Local Control and Pneumonitis After Stereotactic Body Radiation Therapy for Lung Tumors.
Parker SM; Siochi RA; Wen S; Mattes MD
Pract Radiat Oncol; 2019 Jan; 9(1):e90-e97. PubMed ID: 30267899
[TBL] [Abstract][Full Text] [Related]
15. Letter to the editor of radiotherapy and oncology regarding of the article "Dosimetric parameters related to occurrence of distant metastases and regional nodal relapse after SBRT for early-stage non-small cell lung cancer" by Lalonde et al.
Yang K; Sun C; Yin R
Radiother Oncol; 2022 Dec; 177():240-241. PubMed ID: 35716839
[No Abstract] [Full Text] [Related]
16. Response to "Letter to the editor of radiotherapy and oncology regarding of the article "Dosimetric parameters related to occurrence of distant metastases and regional nodal relapse after SBRT for early-stage non-small cell lung cancer" by Lalonde et al.".
Lalonde R; Abdelhakiem M; Keller A; Huq MS
Radiother Oncol; 2022 Dec; 177():242. PubMed ID: 35716840
[No Abstract] [Full Text] [Related]
17. The impact of histology and delivered dose on local control of spinal metastases treated with stereotactic radiosurgery.
Yamada Y; Katsoulakis E; Laufer I; Lovelock M; Barzilai O; McLaughlin LA; Zhang Z; Schmitt AM; Higginson DS; Lis E; Zelefsky MJ; Mechalakos J; Bilsky MH
Neurosurg Focus; 2017 Jan; 42(1):E6. PubMed ID: 28041329
[TBL] [Abstract][Full Text] [Related]
18. Stereotactic body radiation therapy (SBRT) improves local control and overall survival compared to conventionally fractionated radiation for stage I non-small cell lung cancer (NSCLC).
von Reibnitz D; Shaikh F; Wu AJ; Treharne GC; Dick-Godfrey R; Foster A; Woo KM; Shi W; Zhang Z; Din SU; Gelblum DY; Yorke ED; Rosenzweig KE; Rimner A
Acta Oncol; 2018 Nov; 57(11):1567-1573. PubMed ID: 29873277
[TBL] [Abstract][Full Text] [Related]
19. Comparison of accelerated hypofractionation and stereotactic body radiotherapy for Stage 1 and node negative Stage 2 non-small cell lung cancer (NSCLC).
Lucas JT; Kuremsky JG; Soike M; Hinson WW; Kearns WT; Hampton CJ; Blackstock AW; Urbanic J
Lung Cancer; 2014 Jul; 85(1):59-65. PubMed ID: 24813936
[TBL] [Abstract][Full Text] [Related]
20. Five-fraction SBRT for ultra-central NSCLC in-field recurrences following high-dose conventional radiation.
Repka MC; Aghdam N; Kataria SK; Campbell L; Suy S; Collins SP; Anderson E; Lischalk JW; Collins BT
Radiat Oncol; 2017 Oct; 12(1):162. PubMed ID: 29052514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
